WEST LAFAYETTE, Ind., March 5, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the FDA has approved the importation of Endocyte’s supply of Doxil® from Europe into the U.S. for use in the PROCEED Phase 3 trial.
